<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043589</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH035182</org_study_id>
    <secondary_id>R01MH035182</secondary_id>
    <nct_id>NCT00043589</nct_id>
  </id_info>
  <brief_title>Memory and Mental Health in Aging</brief_title>
  <official_title>Memory and Mental Health in Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of donepezil (AriceptÂ®) and cognitive training in&#xD;
      improving memory performance in elderly adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug donepezil plus cognitive training may work better than cognitive training alone to&#xD;
      improve the memory of nondemented older adults. In this study, participants are assigned&#xD;
      randomly to receive either donepezil plus cognitive training or placebo plus cognitive&#xD;
      training. Memory and quality of life tests are used to evaluate the effects of the study&#xD;
      treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Memory Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Memory-training class</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mini-Mental Exam score between 24 and 30&#xD;
&#xD;
          -  Hamilton Depression Score of 12 or less on 17-item scale&#xD;
&#xD;
          -  Visual and auditory acuity adequate for neuropsychological testing&#xD;
&#xD;
          -  General good health (no additional diseases expected to interfere with the study)&#xD;
&#xD;
          -  Normal B12, Rapid Plasma Reagin (RPR), and Thyroid Function Tests&#xD;
&#xD;
          -  Normal general clinical chemistry, complete blood count, and electrocardiogram (ECG)&#xD;
&#xD;
          -  Female participants must be 2 years postmenopausal or surgically sterile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant neurologic disease&#xD;
&#xD;
          -  Possible or probable Alzheimer's Disease (AD)&#xD;
&#xD;
          -  Parkinson's disease&#xD;
&#xD;
          -  Multi-infarct dementia&#xD;
&#xD;
          -  Huntington's disease&#xD;
&#xD;
          -  Normal pressure hydrocephalus&#xD;
&#xD;
          -  Brain tumor&#xD;
&#xD;
          -  Progressive supranuclear palsy&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Subdural hematoma&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  History of significant head trauma followed by persistent neurologic defaults or known&#xD;
             structural brain abnormalities&#xD;
&#xD;
          -  Major depression or other major psychiatric disorder as described in DSM IV within the&#xD;
             past 2 years&#xD;
&#xD;
          -  Psychotic features, agitation, or behavioral problems within the last 3 months&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years&#xD;
&#xD;
          -  Significant systemic illness or unstable medical condition including: a) history of&#xD;
             systemic cancer within the last 5 years (nonmetastatic skin cancers are acceptable);&#xD;
             b) history of myocardial infarction within the past year or unstable or severe&#xD;
             cardiovascular disease, including angina or CHF with symptoms at rest; c) clinically&#xD;
             significant obstructive pulmonary disease or asthma; d) clinically significant and&#xD;
             unstable gastrointestinal disorder such as ulcer disease or a history of active or&#xD;
             occult gastrointestinal bleeding within 2 years; e) clinically significant laboratory&#xD;
             test abnormalities on the battery of screening tests (hematology, prothrombin time,&#xD;
             chemistry, urinalysis, ECG); f) insulin-requiring diabetes or uncontrolled diabetes&#xD;
             mellitus; g) uncontrolled hypertension (systolic BP greater than 170 or diastolic&#xD;
             greater than 100); h) history of clinically significant liver disease, coagulopathy,&#xD;
             or vitamin K deficiency within the past 2 years&#xD;
&#xD;
          -  Use of centrally active beta-blockers, narcotics, methyldopa, and clonidine within 4&#xD;
             weeks prior to screening&#xD;
&#xD;
          -  Use of anti-Parkinsonian medications (e.g. Sinemet, amantadine, bromocriptine,&#xD;
             pergolide, and selegiline) within 2 months prior to screening&#xD;
&#xD;
          -  Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening&#xD;
&#xD;
          -  Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screening&#xD;
&#xD;
          -  Use of short-acting anxiolytics or sedative hypnotics more frequently than 2 times per&#xD;
             week within 4 weeks prior to screening (note: sedative agents should not be used&#xD;
             within 72 hours of screening)&#xD;
&#xD;
          -  Initiation or change in dose of an antidepressant lacking significant cholinergic side&#xD;
             effects within the 4 weeks prior to screening (use of stable doses of antidepressants&#xD;
             for at least 4 weeks prior to screening is acceptable)&#xD;
&#xD;
          -  Use of systemic corticosteroids within 3 months prior to screening&#xD;
&#xD;
          -  Medications with significant cholinergic or anticholinergic side effects (e.g.&#xD;
             pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within 4 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Use of anti-convulsants (e.g. Phenytoin, Phenobarbital, Carbamazepine) within 2 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Use of warfarin (Coumadin) within 4 weeks prior to screening&#xD;
&#xD;
          -  Prior use of any FDA approved medications for the treatment of AD (e.g. tacrine,&#xD;
             donepezil, or other newly approved medications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aging Clinical Research Center, VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>August 9, 2002</study_first_submitted>
  <study_first_submitted_qc>August 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2002</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

